These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 25727038)

  • 1. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and concordance of high cardiovascular disease scores in HIV/AIDS patients from Croatia and Serbia with four international algorithms.
    Begovac J; Dragovic G; Viskovic K; Kusic J; Mihanovic MP; Lukas D; Jevtovic D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19549. PubMed ID: 25394056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
    Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
    JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
    Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH
    JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.
    Mortensen MB; Nordestgaard BG; Afzal S; Falk E
    Eur Heart J; 2017 Feb; 38(8):586-594. PubMed ID: 28363217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.
    Delabays B; de La Harpe R; Vollenweider P; Fournier S; Müller O; Strambo D; Graham I; Visseren FLJ; Nanchen D; Marques-Vidal P; Vaucher J
    Eur J Prev Cardiol; 2023 Nov; 30(17):1856-1864. PubMed ID: 37290056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study.
    Hamoui O; Omar MI; Raal FJ; Rashed W; Kane A; Alami M; Abreu P; Mashhoud W; Alsheikh-Ali AA
    BMC Cardiovasc Disord; 2019 Mar; 19(1):61. PubMed ID: 30876390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
    Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
    JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease.
    Ofori S; Dodiyi-Manuel S; Akpa MR
    J Clin Lipidol; 2017; 11(6):1441-1447. PubMed ID: 29050979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Guidelines for Statin Treatment in Canada and the United States.
    Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models.
    Krikke M; Hoogeveen RC; Hoepelman AI; Visseren FL; Arends JE
    HIV Med; 2016 Apr; 17(4):289-97. PubMed ID: 26268806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Flueckiger P; Qureshi W; Michos ED; Blaha M; Burke G; Sandfort V; Herrington D; Yeboah J
    Clin Cardiol; 2017 Mar; 40(3):163-169. PubMed ID: 27859433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
    Mortensen MB; Nordestgaard BG
    JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
    Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
    Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses.
    Garg N; Muduli SK; Kapoor A; Tewari S; Kumar S; Khanna R; Goel PK
    Indian Heart J; 2017; 69(4):458-463. PubMed ID: 28822511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease risk prediction by the American College of Cardiology (ACC)/American Heart Association (AHA) Atherosclerotic Cardiovascular Disease (ASCVD) risk score among HIV-infected patients in sub-Saharan Africa.
    Mosepele M; Hemphill LC; Palai T; Nkele I; Bennett K; Lockman S; Triant VA
    PLoS One; 2017; 12(2):e0172897. PubMed ID: 28235058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.